{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=38",
    "query": {
      "condition": "Cancer Pediatric",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1302,
    "total_pages": 131,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T08:50:15.664Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01200017",
      "title": "Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Lymphomas",
        "Bone Marrow Failure",
        "Hemoglobinopathy",
        "Immune Deficiency",
        "Osteopetrosis",
        "Cytopenias",
        "Leukocyte Disorders",
        "Anemia Due to Intrinsic Red Cell Abnormality"
      ],
      "interventions": [
        {
          "name": "CD34+ enriched, T Cell Depleted donor stem cell product",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Christopher Dvorak",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Months to 30 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01200017"
    },
    {
      "nct_id": "NCT03823950",
      "title": "Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Granulocyte Colony-Stimulating Factor",
        "Chemotherapy-induced Neutropenia",
        "Chemotherapy-Induced Febrile Neutropenia",
        "Pediatric Cancer"
      ],
      "interventions": [
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 150,
      "start_date": "2019-02-01",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823950"
    },
    {
      "nct_id": "NCT01460160",
      "title": "Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Pediatric"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 106,
      "start_date": "2012-04-13",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01460160"
    },
    {
      "nct_id": "NCT07297979",
      "title": "Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Xaluritamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-04-08",
      "completion_date": "2030-05-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07297979"
    },
    {
      "nct_id": "NCT04222413",
      "title": "Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Pancreatic Cancer",
        "Pediatric Solid Tumor",
        "Advanced Breast Cancer",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Metarrestin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 116,
      "start_date": "2020-10-27",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 2,
      "location_summary": "Fairway, Kansas • Bethesda, Maryland",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04222413"
    },
    {
      "nct_id": "NCT06161974",
      "title": "Study of Olutasidenib and Temozolomide in HGG",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Astrocytoma",
        "Astrocytoma, Grade III",
        "Astrocytoma, Grade IV",
        "Diffuse Intrinsic Pontine Glioma",
        "WHO Grade III Glioma",
        "WHO Grade IV Glioma",
        "Metastatic Brain Tumor",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Thalamus Tumor",
        "Spinal Tumor",
        "IDH1 Mutation",
        "IDH1 R132",
        "IDH1 R132C",
        "IDH1 R132H",
        "IDH1 R132S",
        "IDH1 R132G",
        "IDH1 R132L",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Olutasidenib + TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "12 Years to 39 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-02-01",
      "completion_date": "2035-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161974"
    },
    {
      "nct_id": "NCT02676323",
      "title": "Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Intrathecal Triples",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "Up to 24 Years"
      },
      "enrollment_count": 19,
      "start_date": "2016-05-03",
      "completion_date": "2018-04-09",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02676323"
    },
    {
      "nct_id": "NCT03043391",
      "title": "Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligoastrocytoma",
        "Anaplastic Oligodendroglioma",
        "Glioblastoma",
        "Gliosarcoma",
        "Atypical Teratoid/Rhabdoid Tumor of Brain",
        "Medulloblastoma",
        "Ependymoma",
        "Pleomorphic Xanthoastrocytoma of Brain",
        "Embryonal Tumor of Brain"
      ],
      "interventions": [
        {
          "name": "Polio/Rhinovirus Recombinant (PVSRIPO)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Istari Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2017-11-07",
      "completion_date": "2022-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043391"
    },
    {
      "nct_id": "NCT00993694",
      "title": "Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Methemoglobinemia",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Nonmalignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "dapsone",
          "type": "DRUG"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 41,
      "start_date": "2009-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993694"
    },
    {
      "nct_id": "NCT01644773",
      "title": "Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "High-grade Glioma"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-11-27",
      "completion_date": "2018-09-28",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-26T08:50:15.664Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644773"
    }
  ]
}